Adjustments to Current Assets
Adjustments to Total Assets
Adjustments to Current Liabilities
Adjustments to Total Liabilities
Adjustments to Stockholders’ Equity
Adjustments to Capitalization Table
Adjustments to Reported Income

Pfizer Inc., adjusted current assets

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Current assets	43,333)	51,259)	59,693)	35,067)	32,803)
Adjustments
Add: Allowance for doubtful accounts	470)	449)	492)	508)	527)
After Adjustment
Adjusted current assets	43,803)	51,708)	60,185)	35,575)	33,330)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Download chart

Pfizer Inc., adjusted total assets

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Total assets	226,501)	197,205)	181,476)	154,229)	167,489)
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Add: Allowance for doubtful accounts	470)	449)	492)	508)	527)
Less: Noncurrent deferred tax assets (included in Noncurrent deferred tax assets and other noncurrent tax assets)²	1,768)	4,769)	1,618)	940)	878)
After Adjustment
Adjusted total assets	225,203)	192,885)	180,350)	153,797)	167,138)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

² Noncurrent deferred tax assets (included in Noncurrent deferred tax assets and other noncurrent tax assets). See details »

Download chart

Pfizer Inc., adjusted current liabilities

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Current liabilities	47,794)	42,138)	42,671)	25,920)	37,304)
Adjustments
Less: Current restructuring accruals	1,325)	991)	816)	628)	714)
After Adjustment
Adjusted current liabilities	46,469)	41,147)	41,855)	25,292)	36,590)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Download chart

Pfizer Inc., adjusted total liabilities

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Total liabilities	137,213)	101,288)	104,013)	90,756)	104,042)
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Less: Noncurrent deferred tax liabilities²	640)	1,023)	349)	4,063)	5,578)
Less: Restructuring accruals	1,988)	1,204)	1,071)	798)	933)
After Adjustment
Adjusted total liabilities	134,585)	99,061)	102,593)	85,895)	97,531)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Noncurrent deferred tax liabilities. See details »

Download chart

Pfizer Inc., adjusted total Pfizer Inc. shareholders’ equity

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Total Pfizer Inc. shareholders’ equity	89,014)	95,661)	77,201)	63,238)	63,143)
Adjustments
Less: Net deferred tax asset (liability)¹	1,128)	3,746)	1,269)	(3,123)	(4,700)
Add: Allowance for doubtful accounts	470)	449)	492)	508)	527)
Add: Restructuring accruals	1,988)	1,204)	1,071)	798)	933)
Add: Equity attributable to noncontrolling interests	274)	255)	261)	235)	304)
After Adjustment
Adjusted total equity	90,618)	93,823)	77,756)	67,902)	69,607)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ Net deferred tax asset (liability). See details »

Download chart

Pfizer Inc., adjusted capitalization table

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Short-term borrowings, including current portion of long-term debt	10,350)	2,945)	2,241)	2,703)	16,195)
Long-term debt, excluding current portion	61,538)	32,884)	36,195)	37,133)	35,955)
Total reported debt	71,888)	35,829)	38,436)	39,836)	52,150)
Total Pfizer Inc. shareholders’ equity	89,014)	95,661)	77,201)	63,238)	63,143)
Total reported capital	160,902)	131,490)	115,637)	103,074)	115,293)
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Add: Operating lease liabilities, short-term (included in Other current liabilities)²	527)	620)	449)	321)	276)
Add: Operating lease liabilities, long-term (included in Other noncurrent liabilities)³	2,626)	2,597)	2,510)	1,114)	1,048)
Adjusted total debt	75,041)	39,046)	41,395)	41,271)	53,474)
Adjustments to Equity
Less: Net deferred tax asset (liability)⁴	1,128)	3,746)	1,269)	(3,123)	(4,700)
Add: Allowance for doubtful accounts	470)	449)	492)	508)	527)
Add: Restructuring accruals	1,988)	1,204)	1,071)	798)	933)
Add: Equity attributable to noncontrolling interests	274)	255)	261)	235)	304)
Adjusted total equity	90,618)	93,823)	77,756)	67,902)	69,607)
After Adjustment
Adjusted total capital	165,659)	132,869)	119,151)	109,173)	123,081)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Operating lease liabilities, short-term (included in Other current liabilities). See details »

³ Operating lease liabilities, long-term (included in Other noncurrent liabilities). See details »

⁴ Net deferred tax asset (liability). See details »

Download chart

Pfizer Inc., adjusted net income attributable to Pfizer Inc.

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Net income attributable to Pfizer Inc.	2,119)	31,372)	21,979)	9,616)	16,273)
Adjustments
Add: Deferred income tax expense (benefit)¹	(3,443)	(3,764)	(4,293)	(1,468)	427)
Add: Increase (decrease) in allowance for doubtful accounts	21)	(43)	(16)	15)	(14)
Add: Increase (decrease) in restructuring accruals	784)	133)	273)	(18)	(319)
Less: Discontinued operations, net of tax	(14)	6)	(434)	2,631)	4)
Add: Other comprehensive income (loss) before allocation to noncontrolling interests	330)	(2,422)	(590)	14)	(376)
Add: Comprehensive income (loss), net of tax, attributable to noncontrolling interest	26)	20)	42)	27)	18)
After Adjustment
Adjusted net income before allocation to noncontrolling interests	(149)	25,290)	17,829)	5,555)	16,005)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ Deferred income tax expense (benefit). See details »

Download chart

Pfizer Inc. (NYSE:PFE)

Adjustments to Financial Statements

Adjustments to Current Assets

Adjustments to Total Assets

Adjustments to Current Liabilities

Adjustments to Total Liabilities

Adjustments to Stockholders’ Equity

Adjustments to Capitalization Table

Adjustments to Reported Income